RxDoctor Payments Data

Robert Clampitt, MD

Family Medicine · Marion, VANPI 1225090509

Payments from drug & device makers

$8,499in general payments, 2019–2025

Across 541 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$877
  • GSK$705
  • AbbVie$687
  • Johnson & Johnson$612
  • Otsuka America Pharmaceutical, Inc.$437
  • plus $4K from 43 others

What the payments were for

  • Speaking & faculty fees$701%
  • Food & beverage$8,42399%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,499 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$176,182
Medicare patients
259
Services billed
3,075

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide140$190,712
EliquisApixaban360$132,927
XareltoRivaroxaban123$78,419
Trelegy ElliptaFluticasone/Umeclidin/Vilanter102$76,024
OtezlaApremilast31$66,379
RexultiBrexpiprazole89$65,142
Tresiba Flextouch U-100Insulin Degludec78$52,359
TrulicityDulaglutide37$46,456
EntrestoSacubitril/Valsartan90$39,942
Tresiba Flextouch U-200Insulin Degludec42$37,629
FarxigaDapagliflozin Propanediol41$33,810
XifaxanRifaximin19$30,029
VraylarCariprazine Hcl32$29,517
MounjaroTirzepatide24$27,956
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$23,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$877$190,712140 claims
PfizerEliquis$270$132,927360 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Incruse Ellipta$705$92,962149 claims
Johnson & JohnsonXarelto$612$78,419123 claims
Lilly USA, LLCTrulicity, Mounjaro$293$74,41261 claims
AmgenOtezla$350$66,37931 claims
Otsuka America Pharmaceutical, Inc.Rexulti$437$65,14289 claims
AbbVieVraylar, Linzess$687$50,95059 claims
AstraZenecaFarxiga, Symbicort, Brilinta$1,581$50,77476 claims
NovartisEntresto$207$39,94290 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$128$30,02919 claims
Boehringer IngelheimJardiance, Spiriva Respimat$29$22,58029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Marion

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →